Gala­pa­gos finds Pol­ish part­ner for in­flam­ma­tion drugs; Zai Lab's Ze­ju­la app gets speedy re­view in Chi­na

→ Bel­gium’s Gala­pa­gos and Pol­ish biotech Ryvu are part­ner­ing on a dis­cov­ery and de­vel­op­ment pact for in­flam­ma­tion drugs. Ryvu will do the ear­ly dis­cov­ery work while Gala­pa­gos has rights to li­cense the IP. Ryvu gets an un­spec­i­fied amount up­front and mile­stones in the deal.

→ Chi­na’s Zai Lab re­ports that Chi­na’s reg­u­la­to­ry au­thor­i­ties pro­vid­ed a pri­or­i­ty re­view for their sN­DA to use Ze­ju­la as a front­line main­te­nance ther­a­py for ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER